A device for intravitreal and endolymphatic drug administration and reflexogenic zone blockade in ophthalmology

Currently, most surgeons use 27G needles to perform intravitreal and endolymphatic administration and reflexogenic zone blockade. However, their use is associated with certain disadvantages and complications.

Aim. To develop a device for intravitreal and endolymphatic drug administration and sinocarotid zone blockade.

Methods. A device for intravitreal and endolymphatic drug administration and sinocarotid zone blockade was developed. It consists of an original adapter, 30G carpule needle, and a syringe. Pre-clinical trials included comparative evaluation of this device and a rather well-known instrument for intravitreal and endolymphatic drug administration and sinocarotid zone blockade (a syringe with 27G needle). Clinical trials involved 150 patients aged 36 years and older.

Results. The device consists of a syringe, 30G carpule needle, and an original three-stage hollow adapter that attaches the needle to the syringe. The needle has a cannula to be attached to the adapter. The cannula and the second stage of the adapter have the thread with an aligning arrangement The third stage of the adapter is made in a form of a truncated cone that tightly goes into the cannula thus providing reliable fixation of the needle. The device: (1) minimizes the leakage of a drug in the course of the procedure thus providing more accurate drug administration and preventing its overuse; (2) reduces complication risk and improves the safety of intravitreal and endolymphatic drug administration and sinocarotid zone blockade; (3) improves the tolerability of intravitreal and endolymphatic drug administration and sinocarotid zone blockade; (4) improves personal readiness to undergo maintenance retreatment. The utility model application was filed, and the filing receipt No. 2014109466 was acquired on March 12, 2014.

Conclusion. The device provides optimal intravitreal and endolymphatic drug administration and sinocarotid zone blockade.

1. Boyko E. V., Sosnovsky S. V., Berezin R. D. et al. [Intravitreal injections: theory and practice]. Intravitreal’nye in’ektsii: teoriya i praktika [Ophthalmic Vedomosti]. Oftal’mologicheskie vedomosti 2010; III (2): 28‑35. (in Russ.).

2. Egorov E. A., Alekseev V., Astakhov YU.S. et al. [Rational pharmacotherapy in ophthalmology. A guide for physicians, 2‑nd edition.] Racional’naja farmakoterapija v oftal’mologii. Moscow: «Littera», 2011. 1059 p. (in Russ.).

3. Eremenko A. I., Kalenich L. A., Yanchenko S. V. [Clinical efficacy of endolymphatic regional administration, inracarotid infusion of drugs and blockades of sinocarotid zone in the treatment of ischemic optic neuropathy]. Klinicheskaya effektivnost’ sposobov endolimfaticheskogo regionarnogo vvedeniya, vnutrikarotidnoi infuzii lekarstvennykh preparatov i blokad sinokarotidnoi zony v lechenii ishemicheskikh opticheskikh neiropatii. [Ophthalmology journal]. Oftal’mologicheskij zhurnal 2006;3: 151‑153. (in Russ.).

4. Eremenko A. I., Yanchenko S. V. [Age-related form of dry eye syndrome therapy optimization] [Ophthalmic Vedomosti]. Optimizatsiya terapii vozrastnoi formy sindroma «sukhogo glaza. Oftal’mologicheskie vedomosti 2010; III (2): 73‑80. (in Russ.).

5. Maksimov I. B., Neroev V. V. [Retinalamin. Neuroprotection in ophthalmology.] Retinalamin. Nejroprotekcija v oftal’mologii. SPb.: Nauka, 2007. 160 p. (in Russ.).

6. Neroev V. V., Tankovskyi W. E., Grigoriev A. V., Serebryakova P. U., Urakova N. A. [The changes of visual acuity and platelet aggregation in patients with retinal vein occlusion acconbained by angiitis after a single intravitreal injection of bevacizumab]. Vliyanie odnokratnogo vvedeniya bevatsizumaba na ostrotu zreniya i agregatsiyu trombotsitov u bol’nykh s trombozom ven setchatki na fone angiita. [Russian ophthalmological journal]. Rossijskij oftal’mologicheskij zhurnal 2013; 6: (3): 67‑71. (in Russ.).

7. Yanchenko S. V., Eremenko A. I. [The possibility of using lymphotropic therapy in the treatment of dry eye syndrome]. Blokady sinokarotidnoy refleksogennoy zony v kompleksnoy terapii vtorichnogo kombinirovannogo giposekretornogo sindroma «sukhogo glaza». [Clinical ophthalmology]. Klinicheskaja oftal’mologija 2008; XV (3): 197‑199. (in Russ.).

8. Yanchenko S. V., Eremenko A. I. [The possibility of using lymphotropic therapy in the treatment of dry eye syndrome]. Vozmozhnosti ispol’zovaniya limfotropnoi terapii v lechenii sindroma «sukhogo glaza». [Clinical ophthalmology]. Klinicheskaja oftal’mologija 2010;1: 20‑23. (in Russ.).

9. Aiello L. P., Brocker A. J., Chang S. et al. Evolving guidelines for intravitreal injections. Retina. 2004; 24: 3‑19.

10. Martin D. F., Maguire M. G., Fine S. L. et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration; two-year results. Ophthalmology 2012:;119: 1388‑1398.

11. Peyman G. A., Lad E. M., Moshfeghi D. M. Intravitreal injection of therapeutic agents. Retina 2009; 29: 181‑189.

12. Davis M. J., Pollack J. S., Shott S. Comparison of topical anesthetics for intravitreal injections: a randomized clinical trial. Retina 2012; 32: 701‑705.

13. Prenner J. L. Anesthesia for intravitreal injection [Editorial]. Retina 2011; 31: 433‑434.

14. Wagner R. S., Abelson M. et al. Evaluation of moxifloxacin, gatifloxacin, ofloxacin and levofloxacin concentrations in human conjunctival tissue. Arch. Ophthal. 2005; 123: 1282‑1283.